Marlon Trottmann / Shutterstock.com
7 November 2022AmericasStaff Writer
SCOTUS agrees to hear Amgen revival bid
The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
Big Pharma
10 November 2022 Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
Editor's picks
Editor's picks
Americas
25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
Big Pharma
10 November 2022 Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
Americas
25 November 2021 Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
Big Pharma
10 November 2022 Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.